Horizon Pharma PLC (HZNP) was Upgraded by Morgan Stanley to ” Equal-Weight” and the brokerage firm has set the Price Target at $24. Earlier the firm had a rating of “Underweight ” on the company shares. Morgan Stanley advised their investors in a research report released on Jul 11, 2016.
Many Wall Street Analysts have commented on Horizon Pharma PLC. Morgan Stanley Upgraded Horizon Pharma PLC on Jul 11, 2016 to ” Equal-Weight”, Price Target of the shares are set at $24.Goldman Initiated Horizon Pharma PLC on Jun 6, 2016 to “Buy”, Price Target of the shares are set at $24.Shares were Reiterated by Mizuho on May 10, 2016 to “Buy” and Lowered the Price Target to $ 24 from a previous price target of $25 .
On the company’s financial health, Horizon Pharma PLC reported $0.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 9, 2016. Analyst had a consensus of $0.31. The company had revenue of $204.69 million for the quarter, compared to analysts expectations of $197.27 million. The company’s revenue was up 80.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.18 EPS.
Horizon Pharma PLC opened for trading at $18.38 and hit $18.8 on the upside on Friday, eventually ending the session at $18.71, with a gain of 2.86% or 0.52 points. The heightened volatility saw the trading volume jump to 33,45,479 shares. Company has a market cap of $3,000 M.
In a different news, on Jun 15, 2016, Virinder Nohria (director) sold 25,000 shares at $17.69 per share price. According to the SEC, on Dec 10, 2015, Jeffrey W Sherman (EVP and Chief Medical Officer) sold 4,456 shares at $20.00 per share price. On Aug 21, 2015, Thomas Watkins (director) purchased 10,000 shares at $31.32 per share price, according to the Form-4 filing with the securities and exchange commission.
Horizon Pharma plc formerly Vidara Therapeutics International Public Limited Company is a specialty biopharmaceutical company focused on identifying developing acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis inflammation and orphan diseases. The Company’s the United States marketed products are ACTIMMUNE (interferon gamma-1b) DUEXIS (ibuprofen/famotidine) PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA has the United States rights to VIMOVO has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.